{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:13:42Z","timestamp":1772043222535,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1124\/jpet.102.037002","type":"journal-article","created":{"date-parts":[[2003,1,10]],"date-time":"2003-01-10T18:48:30Z","timestamp":1042224510000},"page":"540-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":172,"title":["Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-\u03b1 Fusion Protein in Cynomolgus Monkeys"],"prefix":"10.1016","volume":"303","author":[{"given":"Blaire L.","family":"Osborn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik S.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardetta","family":"Nardelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe X.H.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Moody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liubov S.","family":"Zaritskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.102.037002_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1089-3261(05)70237-3","article-title":"Overview of interferon therapy for chronic hepatitis C.","volume":"3","author":"Ahmed","year":"1999","journal-title":"Clin Liver Dis"},{"key":"10.1124\/jpet.102.037002_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of Interferon: a 40 kDa branched polyethylene glycol-conjugated interferon \u03b12a for the treatment of hepatitis C.","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjug Chem"},{"key":"10.1124\/jpet.102.037002_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00411079","article-title":"A novel class of vector for yeast transformation.","volume":"1","author":"Chinery","year":"1989","journal-title":"Curr Genet"},{"key":"10.1124\/jpet.102.037002_bib4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/cdd.1985.2.247","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular and intraventricular delivery.","volume":"2","author":"Collins","year":"1985","journal-title":"Cancer Drug Deliv"},{"key":"10.1124\/jpet.102.037002_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/00365520150218129","article-title":"Sustained virological response in chronic hepatitis C patients after a 6- and a 36-month interferon-alpha2b treatment schedule: a multicenter, randomized, controlled study.","volume":"36","author":"Damen","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"10.1124\/jpet.102.037002_bib6","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa.","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.102.037002_bib7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2141.1996.00392.x","article-title":"Induction of interferon regulatory factors, 2\u2032-5\u2032 oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.","volume":"92","author":"Fischer","year":"1996","journal-title":"Br J Haematol"},{"issue":"1006","key":"10.1124\/jpet.102.037002_bib8","first-page":"69","article-title":"Drugs for non-HIV viral infections.","volume":"39","year":"1997","journal-title":"Med Lett Drugs Ther"},{"key":"10.1124\/jpet.102.037002_bib9","unstructured":"Food and Drug Administration. Toxicologist\u2019s Review, BLA 99-1488, (2000)"},{"key":"10.1124\/jpet.102.037002_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-2007-1007205","article-title":"Interferons in host defense.","volume":"17","author":"Foster","year":"1997","journal-title":"Semin Liver Dis"},{"key":"10.1124\/jpet.102.037002_bib11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-2007-1007265","article-title":"Therapy of hepatitis C.","volume":"15","author":"Fried","year":"1995","journal-title":"Semin Liver Dis"},{"key":"10.1124\/jpet.102.037002_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-\u03b12b: pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data.","volume":"68","author":"Glue","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.102.037002_bib13","unstructured":"Hinchliffe E, Chinery SA. inventors, Delta Biotechnology Limited, assignee. European patent 0286424. 1994, March 16, 1994"},{"key":"10.1124\/jpet.102.037002_bib14","unstructured":"Hinchliffe E, Chinery SA. inventors, Delta Biotechnology Limited, assignee. US patent 5,637,504. 1997, June 10, (1997)"},{"key":"10.1124\/jpet.102.037002_bib15","first-page":"1","article-title":"Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.","volume":"8","author":"Hu","year":"2001","journal-title":"J Viral Hepatitis"},{"key":"10.1124\/jpet.102.037002_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jir.1983.3.425","article-title":"Cell and virus sensitivity studies with recombinant human alpha interferons.","volume":"3","author":"Kramer","year":"1983","journal-title":"J Interferon Res"},{"key":"10.1124\/jpet.102.037002_bib17","doi-asserted-by":"crossref","first-page":"39765","DOI":"10.1074\/jbc.M102502200","article-title":"Interferon-\u03ba, a novel type I IFN expressed in human keratinocytes.","volume":"276","author":"LaFleur","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.102.037002_bib18","series-title":"The Cytokine Handbook","first-page":"491","article-title":"Interferons","author":"Maeyer","year":"1998"},{"key":"10.1124\/jpet.102.037002_bib19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1015836720294","article-title":"Interspecies scaling of clearance and volume of distribution for five therapeutic proteins.","volume":"8","author":"Mordenti","year":"1991","journal-title":"Pharm Res (NY)"},{"key":"10.1124\/jpet.102.037002_bib20","first-page":"97","article-title":"Induction of 2\u2032-5\u2032 oligoadenylate synthetase during interferon treatment of chronic myelogenous leukemia.","volume":"4","author":"Moritz","year":"1992","journal-title":"Mol Biother"},{"key":"10.1124\/jpet.102.037002_bib21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2001.19.5.1312","article-title":"Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.","volume":"19","author":"Motzer","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.102.037002_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/1096-9071(200010)62:2<185::AID-JMV9>3.0.CO;2-X","article-title":"Effect of interferon treatment on serum 2\u2032,5\u2032-oligoadenylate synthetase levels in hepatitis C-infected patients.","volume":"62","author":"Murashima","year":"2000","journal-title":"J Med Virol"},{"key":"10.1124\/jpet.102.037002_bib23","series-title":"Applied Multivariate Statistics with SAS Software","author":"Naik","year":"1999"},{"key":"10.1124\/jpet.102.037002_bib24","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2165\/00003495-200161150-00013","article-title":"Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C.","volume":"61","author":"Perry","year":"2001","journal-title":"Drugs"},{"key":"10.1124\/jpet.102.037002_bib25","series-title":"All About Albumin.","author":"Peters","year":"1996"},{"key":"10.1124\/jpet.102.037002_bib26","first-page":"2489","article-title":"Biological properties of recombinant \u03b1-interferons: 40th anniversary of the discovery of interferons.","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.102.037002_bib27","doi-asserted-by":"crossref","first-page":"P755","DOI":"10.1128\/jvi.37.2.755-758.1981","article-title":"Convenient assay for interferon.","volume":"37","author":"Rubinstein","year":"1981","journal-title":"J Virol"},{"key":"10.1124\/jpet.102.037002_bib28","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1074\/jbc.273.14.8003","article-title":"Differences in activity between \u03b1 and \u03b2 type I Interferons explored by mutational analysis.","volume":"273","author":"Runkel","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.102.037002_bib29","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood.V89.9.3243","article-title":"Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin.","volume":"89","author":"Syed","year":"1997","journal-title":"Blood"},{"key":"10.1124\/jpet.102.037002_bib30","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1182\/blood.V98.6.1708","article-title":"Phase I study of polyethylene glycol formulation of interferon \u03b1-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.","volume":"98","author":"Talpaz","year":"2001","journal-title":"Blood"},{"key":"10.1124\/jpet.102.037002_bib31","first-page":"48","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update.","volume":"8","author":"Thevenot","year":"2001","journal-title":"J Viral Hepatitis"},{"key":"10.1124\/jpet.102.037002_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/0168-8278(91)90814-R","article-title":"Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.","volume":"13","author":"Tine","year":"1991","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.102.037002_bib33","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/1097-0142(19860415)57:8+<1648::AID-CNCR2820571303>3.0.CO;2-O","article-title":"The preclinical development of Roferon\u00ae-A.","volume":"57","author":"Trown","year":"1986","journal-title":"Cancer"},{"key":"10.1124\/jpet.102.037002_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/jir.1984.4.399","article-title":"Pharmacokinetics of recombinant alpha A interferon following intravenous infusion and bolus, IM and PO administrations to African green monkeys.","volume":"4","author":"Wills","year":"1984","journal-title":"J Interferon Res"},{"key":"10.1124\/jpet.102.037002_bib35","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1073\/pnas.89.5.1904","article-title":"Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.","volume":"89","author":"Yeh","year":"1992","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524359713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524359713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.102.037002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:29:38Z","timestamp":1740007778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524359713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["S0022356524359713"],"URL":"https:\/\/doi.org\/10.1124\/jpet.102.037002","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and Pharmacodynamic Studies of a Human Serum Albumin-Interferon-\u03b1 Fusion Protein in Cynomolgus Monkeys","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.102.037002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}